Latest & greatest articles for donepezil

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on donepezil or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on donepezil and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for donepezil

21. Health economic effect of donepezil treatment for CDR 0.5 converters to Alzheimer's disease as shown by the Markov model

Health economic effect of donepezil treatment for CDR 0.5 converters to Alzheimer's disease as shown by the Markov model Health economic effect of donepezil treatment for CDR 0.5 converters to Alzheimer's disease as shown by the Markov model Health economic effect of donepezil treatment for CDR 0.5 converters to Alzheimer's disease as shown by the Markov model Kasuya M, Meguro K Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study compared donepezil therapy for patients with a clinical dementia rating (CDR) of 1.0; of 0.5; or of 0.5 who were identified as converters to 1.0. The authors concluded that the annual chance of decline had to be reduced from 15% to 12%, through the detection of CRD 0.5 converters, to produce

2010 NHS Economic Evaluation Database.

22. Atorvastatin does not slow cognitive decline in patients with mild to moderate probable Alzheimer's disease who are taking donepezil

Atorvastatin does not slow cognitive decline in patients with mild to moderate probable Alzheimer's disease who are taking donepezil Atorvastatin does not slow cognitive decline in patients with mild to moderate probable Alzheimer's disease who are taking donepezil | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please (...) are taking donepezil Article Text Therapeutics Atorvastatin does not slow cognitive decline in patients with mild to moderate probable Alzheimer's disease who are taking donepezil Statistics from Altmetric.com Question Question Does atorvastatin improve cognition in patients with mild to moderate Alzheimer's disease (AD)? Patients 640 adults (age 50–90 years) patients with mild to moderate probable AD with a mini-mental state examination (MMSE) score 13–25, and taking donepezil 10 mg daily for ≥3 months

2010 Evidence-Based Mental Health

23. Donepezil for dementia in people with Down syndrome. (PubMed)

Donepezil for dementia in people with Down syndrome. Alzheimer's dementia (AD) is the most common form of dementia in people with Down Syndrome [DS]. Acetylcholine is a chemical found in the brain that has an important role in memory, attention, reason and language. Donepezil a reversible inhibitor of acetylcholinesterase, which is thought to maintain levels of acetylcholine, and is reported to have some benefits for people with AD in the general population. It is important to note that people (...) with DS tend to present with AD at a much younger age than the normal population as well as having subtle differences in physiology (e.g. metabolism and heart rate) and may therefore have different requirements from the general population.To determine the effectiveness and safety of donepezil for people with DS who develop AD.CENTRAL, MEDLINE, EMBASE, CINAHL, PsycINFO, BIOSIS, SCI, SSCI and the NRR were searched up to October 2008. We contacted the manufacturers of donepezil as well as experts

2009 Cochrane

24. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease

Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease Lopez-Bastida J, Hart W, Garcia-Perez L, Linertova R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study evaluated the cost-effectiveness of treatment with donepezil for patients with mild or moderate Alzheimer's disease compared with no drug treatment. The authors concluded that donepezil was cost-effective for patients with mild Alzheimer's disease in Spain. The methods and reporting of the study were adequate and the authors’ conclusions appear

2009 NHS Economic Evaluation Database.

25. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine

Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

26. Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL (PubMed)

Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL Cholinergic deficits might contribute to vascular cognitive impairment. Trials of cholinesterase inhibitors in patients with vascular dementia are difficult because of heterogeneous disease mechanisms and overlap between vascular and Alzheimer's disease (AD) pathology in the age-group recruited. Cerebral autosomal dominant arteriopathy with subcortical infarcts (...) and leucoencephalopathy (CADASIL) is a genetic form of subcortical ischaemic vascular dementia. It represents a homogeneous disease process, and because of CADASIL's early onset, comorbid AD pathology is rare. We did a multicentre, 18-week, placebo-controlled, double-blind, randomised parallel-group trial to determine whether the cholinesterase inhibitor donepezil improves cognition in patients with CADASIL.168 patients with CADASIL (mean age 54.8 years) were assigned to 10 mg donepezil per day (n=86) or placebo (n

2008 EvidenceUpdates

27. Donepezil is no more effective than placebo for agitation in people with Alzheimer’s disease

Donepezil is no more effective than placebo for agitation in people with Alzheimer’s disease Donepezil is no more effective than placebo for agitation in people with Alzheimer’s disease | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Donepezil is no more effective than placebo for agitation in people with Alzheimer’s disease Article Text Therapeutics Donepezil is no more effective than placebo for agitation in people

2008 Evidence-Based Mental Health

28. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis

Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE CRD (...) summary This review concluded that cholinesterase inhibitors (donepezil, galantamine and rivastigmine) were able to stabilise or slow decline in cognition, function, behaviour and global change when compared with placebo. There was no clear evidence to determine whether one of these drugs was more efficacious than another. The review was generally well conducted and the conclusions are likely to be reliable. Authors' objectives To assess the efficacy and safety of cholinesterase inhibitors (donepezil

2008 DARE.

29. Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan

Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan Fuh J L, Wang S J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions (...) followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study assessed the cost-effectiveness of donepezil compared with usual care for the treatment of patients with Alzheimer’s disease. The authors concluded that the use of donepezil in Taiwanese patients was potentially cost-effective, and was also cost-saving from a societal perspective. The study methodology seems robust but the sources used to populate the decision model were

2008 NHS Economic Evaluation Database.

30. The effectiveness of donepezil for cognitive rehabilitation after traumatic brain injury: a systematic review

The effectiveness of donepezil for cognitive rehabilitation after traumatic brain injury: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

31. Neither vitamin E nor donepezil delays progression from amnestic mild cognitive impairment to Alzheimer’s disease in the long te (Full text)

Neither vitamin E nor donepezil delays progression from amnestic mild cognitive impairment to Alzheimer’s disease in the long te Neither vitamin E nor donepezil delays progression from amnestic mild cognitive impairment to Alzheimer’s disease in the long term | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our (...) . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Neither vitamin E nor donepezil delays progression from amnestic mild cognitive impairment to Alzheimer’s disease in the long term

2007 Evidence-Based Mental Health PubMed

32. Donepezil for the treatment of agitation in Alzheimer's disease. (Full text)

Donepezil for the treatment of agitation in Alzheimer's disease. Agitation is a common and distressing symptom in patients with Alzheimer's disease. Cholinesterase inhibitors improve cognitive outcomes in such patients, but the benefits of these drugs for behavioral disturbances are unclear.We randomly assigned 272 patients with Alzheimer's disease who had clinically significant agitation and no response to a brief psychosocial treatment program to receive 10 mg of donepezil per day (128 (...) patients) or placebo (131 patients) for 12 weeks. The primary outcome was a change in the score on the Cohen-Mansfield Agitation Inventory (CMAI) (on a scale of 29 to 203, with higher scores indicating more agitation) at 12 weeks.There was no significant difference between the effects of donepezil and those of placebo on the basis of the change in CMAI scores from baseline to 12 weeks (estimated mean difference in change [the value for donepezil minus that for placebo], -0.06; 95% confidence interval

2007 NEJM PubMed

33. Long-term cost-effectiveness of donepezil for the treatment of Alzheimer's disease

Long-term cost-effectiveness of donepezil for the treatment of Alzheimer's disease Long-term cost-effectiveness of donepezil for the treatment of Alzheimer's disease Long-term cost-effectiveness of donepezil for the treatment of Alzheimer's disease Teipel S J, Ewers M, Reisig V, Schweikert B, Hampel H, Happich M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study determined the cost-effectiveness of donepezil, compared with current care (placebo), for the treatment of Alzheimer's disease in the German setting. The authors concluded that donepezil was a potentially cost-effective alternative to placebo, although the results were highly dependent on the assumptions about treatment effectiveness and remuneration of care-giving

2007 NHS Economic Evaluation Database.

34. Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil

Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil Weycker D, Taneja C, Edelsberg J, Erder M H, Schmitt F A, Setyawan J, Oster G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS (...) EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The aim was to assess the cost-effectiveness of adjuvant memantine in patients with moderate-to-severe Alzheimer’s disease, who were receiving stable doses of donepezil. The authors concluded that memantine plus donepezil improved the clinical outcomes and reduced the total costs of care

2007 NHS Economic Evaluation Database.

35. Donepezil for mild cognitive impairment. (PubMed)

Donepezil for mild cognitive impairment. Problems with memory which do not meet the diagnostic criteria for dementia, usually called mild cognitive impairment (MCI), can be the first sign of an impending dementia, particularly Alzheimer's disease (AD). There is no consensus on a definition or diagnostic criteria for MCI, and MCI remains a vague term and those so described are a heterogeneous population, consisting of people who may rapidly progress to dementia but also of people with stable (...) cognitive deficits and some who may actually improve. Treatment in the very earliest stages of AD may delay progression to AD. Donepezil (Aricept, E2020), a cholinesterase inhibitor, has been shown to benefit all severities of AD including mild and it would be reasonable to investigate its efficacy for those with MCI.To assess the effects of donepezil in people with mild cognitive impairment but no diagnosis of dementia.The trials were identified from a search of the Specialized Register of the Cochrane

2006 Cochrane

36. Long term donepezil did not delay institutionalisation or progression to disability in patients with Alzheimer’s disease (Full text)

Long term donepezil did not delay institutionalisation or progression to disability in patients with Alzheimer’s disease Long term donepezil did not delay institutionalisation or progression to disability in patients with Alzheimer’s disease | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Long term donepezil did not delay institutionalisation or progression to disability in patients with Alzheimer’s disease Article Text

2006 Evidence-Based Medicine (Requires free registration) PubMed

37. Review: donepezil improves cognitive and global function in people with mild to moderate Alzheimer’s disease (Full text)

Review: donepezil improves cognitive and global function in people with mild to moderate Alzheimer’s disease Review: donepezil improves cognitive and global function in people with mild to moderate Alzheimer’s disease | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: donepezil improves cognitive and global function in people with mild to moderate Alzheimer’s disease Article Text Therapeutics Review: donepezil improves cognitive

2006 Evidence-Based Mental Health PubMed

38. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer’s disease

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer’s disease The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from

2006 NIHR HTA programme

39. Donepezil for dementia due to Alzheimer's disease. (PubMed)

Donepezil for dementia due to Alzheimer's disease. Alzheimer's disease is the most common cause of dementia in older people. One of the aims of therapy is to inhibit the breakdown of a chemical neurotransmitter, acetylcholine, by blocking the relevant enzyme. This can be done by a group of chemicals known as cholinesterase inhibitors.The objective of this review is to assess whether donepezil improves the well-being of patients with dementia due to Alzheimer's disease.The Cochrane Dementia (...) and Cognitive Improvement Group's Specialized Register was searched using the terms 'donepezil', 'E2020' and 'Aricept' on 12 June 2005. This Register contains up-to-date records of all major health care databases and many ongoing trial databases. Members of the Donepezil Study Group and Eisai Inc were contacted.All unconfounded, double-blind, randomized controlled trials in which treatment with donepezil was compared with placebo for patients with mild, moderate or severe dementia due to Alzheimer's

2006 Cochrane

40. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. (PubMed)

Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. The cholinesterase inhibitor donepezil is used to treat mild-to-moderate Alzheimer's disease. Its efficacy in severe dementia has not been assessed and is controversial. Our aim was to ascertain the effectiveness of donepezil in patients with severe Alzheimer's disease, by focusing primarily on cognition and activities of daily living.We did a 6-month, double-blind, parallel-group (...) , placebo-controlled study in 248 patients with severe Alzheimer's disease (mini mental state examination score 1-10) who were living in assisted care nursing homes ran by trained staff in Sweden. We assigned patients oral donepezil (5 mg per day for 30 days then up to 10 mg per day thereafter, n=128) or matched placebo (n=120). Our primary endpoints were change from baseline to month 6 in the severe impairment battery (SIB) and modified Alzheimer's Disease Cooperative Study activities of daily living

2006 Lancet